Teva Pharmaceutical Industries seeks further growth

Teva Pharmaceutical Industries’ $40.5bn (€36.2bn) purchase of Allergan’s generics unit, which has formally been completed, doesn’t signal that the Israeli drugmaker will let up its quest for innovative branded medicines.

Efforts to introduce new copycat drugs and integrate operations gained through its largest acquisition “doesn’t mean we confine our business to just generics,” chief executive Erez Vigodman said in an interview at Teva’s headquarters in Petach Tikva in Israel.

“The strategy and vision are much broader.”